Search Results

You searched for: cabazitaxel

SMC Advice

  • cabazitaxel (Jevtana)
    SMC Drug ID: 735/11; Manufacturer: Sanofi-Aventis; Indication: cabazitaxel, in combination with prednisone or prednisolone, is indicated for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.; Submission Type: Resubmission; Status: Not Recommended; Date Advice Published:  13/06/2016;
  • cabazitaxel (Jevtana)
    SMC Drug ID: 735/11; Manufacturer: Sanofi-Aventis; Indication: In combination with prednisone or prednisolone, cabazitaxel is licensed for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. ; Submission Type: Full submission; Status: Not Recommended; Date Advice Published:  07/11/2011;
  • Briefing note: cabazitaxel (Jevtana)

About SMC

  • June 2016 decisions news release
    Treatments for Parkinson’s disease, advanced leukaemia and asthma among four new medicines accepted for routine use in NHS Scotland. The Scottish Medicines Consortium (SMC), which reviews newly...
  • SMC Minutes - Tuesday 04 October 2011
    Minutes of the SMC Meeting held on Tuesday 04 October 2011 Healthcare Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Present: Ms Angela Timoney (Chairman), Ms Sandra Auld, Dr ...
  • SMC Minutes Tuesday 01 November 2011
    Minutes of the SMC Meeting held on Tuesday 01 November 2011 Healthcare Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Present: Ms Angela Timoney (Chairman), Mrs Laura Ace, Ms ...

Help on how to improve your search.